Stock Events

Stock Events

FibroGen 

0
95
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 9Expected
Q1 2026
Q2 2026
Next
-3.19
-1.27
0.65
2.57
Expected EPS
-3.180841391
Actual EPS
N/A

Financials

78.09%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
198.62MRevenue
155.11MNet Income

Analyst Ratings

$27.92Average Price Target
The highest estimate is ⁦32.63⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1FG.STU. It's not an investment recommendation.
Alphabet
2
GOOGL
Main Street Capital
2
MAIN
ExxonMobil
2
XOM
Vale.
2
VALE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Akebia Therapeutics
AKBA
Mkt Cap239.7M
Akebia Therapeutics competes in the anemia market, particularly in chronic kidney disease (CKD), similar to FibroGen's roxadustat.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline competes with FibroGen in developing treatments for anemia associated with CKD, through their product daprodustat.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca collaborates with FibroGen on roxadustat but also competes in broader therapeutic areas relevant to FibroGen's interests.
AMGEN
AMGN
Mkt Cap251.94B
Amgen, with its portfolio of erythropoiesis-stimulating agents (ESAs) for anemia treatment, competes in the same therapeutic area as FibroGen.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other serious diseases, competing with FibroGen's fibrosis research efforts.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical focuses on rare diseases, including some areas that overlap with FibroGen's interest in rare fibrotic conditions.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad portfolio that includes treatments for fibrosis and cancer, directly competing with several of FibroGen's development programs.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences has a strong presence in the treatment of fibrotic diseases, especially with its drug for idiopathic pulmonary fibrosis, competing with FibroGen's fibrosis pipeline.

About

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Show More
CEO
Thane Wettig
Employees
34
Country
United States
ISIN
US31572Q8087
WKN
000A419WK

Listings

F
DE
1FG0.F
STU
DE
1FG0.STU
STU
DE
1FG.STU
XNAS
US
KYNB

0 Comments

Share your thoughts

FAQs

What is FibroGen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange FibroGen stocks are traded under the ticker 1FG.STU.
When is the next FibroGen earnings date?▼
FibroGen is going to release the next earnings report on November 9, 2026.
What were FibroGen earnings last quarter?▼
1FG.STU earnings for the last quarter are 2.57 EUR per share, whereas the estimation was -2.76 EUR resulting in a +192.96% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is FibroGen revenue for the last year?▼
FibroGen revenue for the last year amounts to 198.62M EUR.
What is FibroGen net income for the last year?▼
1FG.STU net income for the last year is 155.11M EUR.
How many employees does FibroGen have?▼
As of November 2, 2026, the company has 34 employees.
In which sector is FibroGen located?▼
FibroGen operates in the Health & Wellness sector.
When did FibroGen complete a stock split?▼
The last stock split for FibroGen was on June 17, 2025 with a ratio of 1:25.
Where is FibroGen headquartered?▼
FibroGen is headquartered in SAN FRANCISCO, United States.